Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor

Juvenescence reported on February 26, 2026, that its PAI-1 inhibitor MDI-2517 completed a Phase 1 trial with a good safety and tolerability profile; a Phase 2 proof-of-concept study is planned.